Today we have part two of our interview with Dr. Francisco Gonzalez-Lima, a behavioral neuroscientist at The University of Texas at Austin. Francisco and his colleagues at the Gonzalez-Lima Lab are recognized as world leaders for their research on the relationship between brain energy metabolism, memory and neurobehavioral disorders. Today’s interview focuses on two interventions Francisco has explored with the aim of protecting people against neurodegeneration: low-dose methylene blue and the application of near-infrared light. Part one of our interview, episode 106, touched on Francisco’s youth and training as well as his early research into Alzheimer’s disease and brain-metabolic mapping. Over the years, much of Francisco’s brain research has focused on transcranial lasers, memory enhancement, neuroprotection, neurocognitive disorders. Current research in the Gonzalez-Lima Lab focuses on the beneficial neurocognitive and emotional effects of noninvasive human brain stimulation in healthy, aging and mentally ill populations. This research primarily uses transcranial infrared laser stimulation and multimodal imaging. Show notes: Today we have part two of our interview with Dr. Francisco Gonzalez-Lima, a behavioral neuroscientist at The University of Texas at Austin. Francisco and his colleagues at the Gonzalez-Lima Lab are recognized as world leaders for their research on the relationship between brain energy metabolism, memory and neurobehavioral disorders. Today’s interview focuses on two interventions Francisco has explored with the aim of protecting people against neurodegeneration: low-dose methylene blue and the application of near-infrared light. Part one of our interview, episode 106, touched on Francisco’s youth and training as well as his early research into Alzheimer’s disease and brain-metabolic mapping. Over the years, much of Francisco’s brain research has focused on transcranial lasers, memory enhancement, neuroprotection, neurocognitive disorders. Current research in the Gonzalez-Lima Lab focuses on the beneficial neurocognitive and emotional effects of noninvasive human brain stimulation in healthy, aging and mentally ill populations. This research primarily uses transcranial infrared laser stimulation and multimodal imaging. [00:04:15] Ken begins part two of our interview mentioning he would like to talk about low-dose methylene blue and the application of near-infrared light. Ken explains that Both of these interventions act by a similar cellular mechanism that targets mitochondrial respiration via the electron transport chain. Ken asks Francisco to describe for listeners what the electron transport chain is and why it is important to the function of the mitochondria. [00:08:22] Dawn asks what the clinical signs and symptoms of unhealthy mitochondrial function are, and what are markers of good mitochondrial health. [00:11:41] Francisco gives an overview of the drug methylene blue, and its mechanism of action. [00:15:02] Ken asks about the origin and history of methylene blue. [00:17:19] Dawn asks about the potential use of methylene blue as treatment for traumatic brain injury. [00:21:10] Ken asks how methylene blue might stimulate neurogenesis. [00:22:42] Dawn mentions that acute brain injury such as stroke and traumatic brain injury involves the upregulation of multiple stress-related responses, she asks how the addition of a hermetic stressor such as methylene blue alters this process. She goes on to ask if there would be an optimal window of time to administer this drug relative to the injury for optimal recovery of function. [00:23:48] Ken asks if methylene blue could be used by an individual before they engage in something that is likely to lead to brain damage, such as boxing, sports, or military operations. [00:26:32] Ken asks about the future of methylene blue in the treatment and prevention of neurodegeneration.